Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

DePinho's STAT3 company Tvardi raises $9M series A

September 21, 2018 5:37 PM UTC

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors.

Tvardi is developing inhibitors of signal transducer and activator of transcription 3 (STAT3) to treat cancer and inflammatory and fibrotic diseases...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article